Shah AK - Search Results

1

Multiple-dose, placebo-controlled, phase I study of oral dolasetron.

Hunt TL, Cramer M, Christy-Bittel J, Shah AK, Meyerson LJ, Benedict CR, Hahne WF. Hunt TL, et al. Among authors: shah ak. Pharmacotherapy. 1996 Mar-Apr;16(2):253-60. Pharmacotherapy. 1996. PMID: 8820469 Clinical Trial.

2

Single-dose, placebo-controlled, phase I study of oral dolasetron.

Dixon RM, Cramer M, Shah AK, Whitmore J, Benedict CR, Hahne WF. Dixon RM, et al. Among authors: shah ak. Pharmacotherapy. 1996 Mar-Apr;16(2):245-52. Pharmacotherapy. 1996. PMID: 8820468 Clinical Trial.

3

Effect of infusion rate on the pharmacokinetics and tolerance of intravenous dolasetron mesylate.

Dimmitt DC, Hunt TL, Spalitto AJ, Cramer MB, Shah AK, Arumugham T, Hahne W. Dimmitt DC, et al. Among authors: shah ak. Ann Pharmacother. 1998 Jan;32(1):39-44. doi: 10.1345/aph.17134. Ann Pharmacother. 1998. PMID: 9475818 Clinical Trial.

4

A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers.

Hunt TL, Cramer M, Shah A, Stewart W, Benedict CR, Hahne WF. Hunt TL, et al. J Clin Pharmacol. 1995 Jul;35(7):705-12. doi: 10.1002/j.1552-4604.1995.tb04111.x. J Clin Pharmacol. 1995. PMID: 7560251 Clinical Trial.

5

Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects.

Hunt TL, Gallagher SC, Cullen MT Jr, Shah AK. Hunt TL, et al. Among authors: shah ak. J Clin Pharmacol. 2005 May;45(5):589-96. doi: 10.1177/0091270005275061. J Clin Pharmacol. 2005. PMID: 15831783 Clinical Trial.

6

Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects.

Shah A, Lanman R, Bhargava V, Weir S, Hahne W. Shah A, et al. Biopharm Drug Dispos. 1995 Apr;16(3):177-89. doi: 10.1002/bdd.2510160303. Biopharm Drug Dispos. 1995. PMID: 7787130 Clinical Trial.

7

Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.

Dimmitt DC, Shah AK, Arumugham T, Cramer MB, Halstenson C, Horton M, Weir SJ. Dimmitt DC, et al. Among authors: shah ak. J Clin Pharmacol. 1998 Sep;38(9):798-806. J Clin Pharmacol. 1998. PMID: 9753207 Clinical Trial.

8

Single- and Multiple-Dose Pharmacokinetics of Reduced Metabolite (MDL 74,156) following Oral Administration of Dolasetron Mesylate to Normal Male Subjects.

Shah A, Lanman R, Bhargava V, Weir S, Hahne W. Shah A, et al. Am J Ther. 1996 May;3(5):364-370. doi: 10.1097/00045391-199605000-00006. Am J Ther. 1996. PMID: 11862273

9

Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.

Shah AK, Hunt TL, Gallagher SC, Cullen MT Jr. Shah AK, et al. Curr Med Res Opin. 2005 Apr;21(4):595-601. doi: 10.1185/030079905X40481. Curr Med Res Opin. 2005. PMID: 15899109 Clinical Trial.

10

Single and multiple oral dose pharmacokinetics of clentiazem in normal volunteers.

Bhargava VO, Shah AK, Weir SJ, Nordbrock EE, Giesing DH. Bhargava VO, et al. Among authors: shah ak. J Clin Pharmacol. 1993 May;33(5):439-43. doi: 10.1002/j.1552-4604.1993.tb04684.x. J Clin Pharmacol. 1993. PMID: 8331200 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

430 results

Search Page

Filters